Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis

Authors

Sabina Babayeva, New York Medical CollegeFollow
Arteni Dyatlov, New York Medical College
Ranjita Pallavi, New York Medical College
Michael Fanucchi, New York Medical CollegeFollow
Carmelo Puccio, New York Medical CollegeFollow
Rocco J. Lafaro, New York Medical CollegeFollow
Fouzia Shakil, New York Medical CollegeFollow
John T. Fallon, New York Medical CollegeFollow
Minghao Zhong, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

2-2016

Department

Surgery

Second Department

Medicine

Recommended Citation

Babayeva, S., Dyatlov, A., Pallavi, R., Fanucchi, M., Puccio, C., Lafaro, R., . . . Zhong, M. (2016). Programmed death ligand-1 (PD-L1) expression in operable non-small cell lung cancer (NSCLC) by immunohistochemical analysis. Modern Pathology, 29(Suppl 2), 467A, doi: 10.1038/modpathol.2016.22.

Publisher's Statement

Originally published in Modern Pathology. doi: 10.1038/modpathol.2016.22